Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 May 2022 12:06

RNS Number : 9686L
MGC Pharmaceuticals Limited
18 May 2022
 

MGC Pharmaceuticals Ltd.

PDMR Notification

18 May 2022

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.

The shares the subject of this notice were issued to the PDMR in accordance with a Share Purchase Agreement executed by MGC Pharma and the owners of MediCaNL Inc in April 2021, with the issued shares being the final tranche of deferred consideration payable by MGC Pharma to the PDMR who was a shareholder of MediCaNL Inc.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Nadya Lisovoder

2

Reason for the notification

 

(a)

Position

 

Chief Medical Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Full name of entity

MGC Pharmaceuticals Limited

 

Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU000000MXC6

(c)

Nature of transaction

Shares issued as consideration for a corporate entity acquired by the Issuer.

(d)

Currency

Price

Volume

Total

AUD

$0.067

6,721,179

450,319

Aggregated information

AUD

$0.067

6,721,179

450,319

(e)

Date of transaction

 

2022-05-13

(f)

Place of transaction

 

Outside a trading venue

 

--Ends--

 

Authorised for release by the Executive Chair, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDUSGBDGDI
Date   Source Headline
6th Apr 202212:02 pmRNSNotification of ASX Market Announcement
5th Apr 20227:00 amRNSDistribution Partnership with Sciensus Rare
10th Mar 20229:10 amRNSJoint Company Secretary Retirement
4th Mar 20224:36 pmRNSDirector/PDMR Shareholding
1st Mar 202211:53 amRNSPrior Share Issues & Admission to Trading
1st Mar 20227:00 amRNSInterim Financial Report
22nd Feb 20228:08 amRNSDirector/PDMR Shareholding
16th Feb 20221:51 pmRNSResult of General Meeting
16th Feb 202212:15 pmRNSShare Issues in 2021
10th Feb 202210:30 amRNSIssue of New Shares Completed in 2021
3rd Feb 202210:42 amRNSDirector/PDMR Shareholding
31st Jan 202211:06 amRNSSecond Price Monitoring Extn
31st Jan 202211:01 amRNSPrice Monitoring Extension
31st Jan 20228:22 amRNSDecember Quarterly Activities Report and Cash Flow
14th Jan 20229:00 amRNSDispatch of General Meeting Documents
6th Jan 20227:00 amRNSImport approval for ArtemiC Rescue in India
20th Dec 20217:00 amRNSClinical Study on influence of ArtemiC Support®
8th Dec 20219:15 amRNSIssue of Shares
6th Dec 20219:30 amRNSPlacing Settlement
30th Nov 20217:00 amRNS£5.5m Capital Raising Completed
29th Nov 202110:06 amRNSDirector/PDMR Shareholding
25th Nov 20217:00 amRNSResult of AGM
24th Nov 20219:00 amRNSCompletion of $1m ArtemiC order to Swiss PharmaCan
24th Nov 20217:00 amRNSIssue of Shares & Extension of Convertible Note
24th Nov 20217:00 amRNSDirector/PDMR Shareholding
22nd Nov 20219:30 amRNSFull Cash Deposit Recieved for US Order of CimetrA
19th Nov 20218:31 amRNSAnnual General Meeting Webinar Information
16th Nov 202111:31 amRNSRelease of Shares from Voluntary Escrow
12th Nov 20219:30 amRNSNotification of ASX Market Announcement
2nd Nov 20217:00 amRNSMalta Production Facility Completion
1st Nov 20217:00 amRNSApproval For Global CimetrA™ Dose Finding Study
26th Oct 20217:00 amRNSSeptember 2021 Quarterly Report & Cash Flow
25th Oct 20211:49 pmRNSDispatch of Annual General Meeting Documents
12th Oct 20217:00 amRNSCimetrATM Investor Presentation
7th Oct 20219:18 amRNSDirector/PDMR Shareholding
6th Oct 20217:08 amRNSAMC USA Places a US$3M Purchase Order for CimetrA
6th Oct 20217:00 amRNSCompany Presentation October 2021
4th Oct 20219:29 amRNSDirector/PDMR Shareholding
30th Sep 20218:00 amRNSAnnual Financial Report
29th Sep 20217:00 amRNSAMC Holdings orders first 1000 units of CimetrA™
22nd Sep 20218:36 amRNSNotification of ASX Market Announcements
20th Sep 202111:03 amRNSDirector/PDMR Shareholding
20th Sep 202110:57 amRNSNotification of ASX Market Announcements
15th Sep 20217:04 amRNSArtemiC Update - Approval for sale in EU & Results
13th Sep 20213:43 pmRNSDirector/PDMR Shareholding
13th Sep 20217:00 amRNSLandmark UK Import Permit granted for CannEpil+
9th Sep 202111:45 amRNSNotification of ASX Market Announcements
9th Sep 202111:35 amRNSNotification of ASX Market Announcements
8th Sep 20219:05 amRNSSecond Price Monitoring Extn
8th Sep 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.